Europe Pain Management Drugs Market is expected to reach US$ 33.77 billion by 2033 | Major key players - Bayer AG, Haleon, Pfizer Plc.

Market Size and Growth:

The Europe Pain Management Drugs Market Size reached US$ 17.13 billion in 2024 and is expected to reach US$ 33.77 billion by 2033, growing at a CAGR of 7.9% during the forecast period of 2025-2033. The Market is rising mainly because chronic pain cases are increasing across Europe and there's stronger adoption of advanced, safer, and more targeted pain medications. According to DataM Intelligence

Get a Free Sample Research PDF: https://datamintelligence.com/download-sample/europe-pain-management-drugs-market?sz

The Europe Pain Management Drugs Market covers the development, approval, and use of medications that alleviate acute and chronic pain across conditions such as arthritis, neuropathy, cancer, and post-operative pain. It includes analgesics, NSAIDs, opioids, antidepressants, anticonvulsants, and emerging non-opioid therapies, driven by aging populations, rising pain prevalence, and ongoing advancements in safer, targeted treatments.

Industry Recent Developments: United States

✅ August 2025: A leading pharmaceutical company received FDA approval for a novel non-opioid chronic pain drug targeting neuropathic pain, expanding options for patients facing opioid restrictions.

✅ September 2025: A U.S.-based biotech firm launched a first-in-class digital therapeutics platform integrated with prescription analgesics to optimize patient adherence and improve real-world pain management outcomes.

✅ October 2025: A collaboration between two European pharmaceutical firms introduced a combination therapy for cancer-related pain into the market, offering a new standard of care via synergy between opioid and non-opioid agents.

Industry Recent Developments: Japan

✅ August 2025: The Japan pain management drugs market sees rising demand driven by chronic pain conditions and muscle spasticity; intrathecal drugs such as baclofen dominate as effective treatments.

✅ September 2025: Increasing prevalence of chronic back pain and muscle spasticity continues to boost the adoption of non-opioid intrathecal drugs, creating lucrative opportunities for pharmaceutical companies.

✅ October 2025: Japan maintains leadership in East Asia for pain management drug market share, supported by initiatives including pain clinics, clinical guidelines, and healthcare professional training in pain management.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/europe-pain-management-drugs-market?sz

Major 2025 FDA Approvals:

✅ JOURNAVXTM (suzetrigine) - a first-in-class, non-opioid oral analgesic for moderate-to-severe acute pain was approved by the FDA on 30 Jan 2025 (Vertex). This approval introduces a new NaV-targeting mechanism that will influence competition in acute-pain prescribing and R&D priorities globally.

✅ TonmyaTM (cyclobenzaprine HCl sublingual tablets) - FDA approved on 15 Aug 2025 for fibromyalgia (first new FDA fibromyalgia treatment in ~15 years). Although this is a U.S. approval, Tonmya's entry into the clinic/market changes the chronic-pain treatment landscape and will likely trigger submission plans and commercialization discussions for Canada / Europe.

Notable 2025 Mergers & Acquisitions:

✅ Eli Lilly → SiteOne Therapeutics (May 27, 2025) - Lilly agreed to acquire SiteOne (up to ~$1B) to add a non-opioid pain candidate (ion-channel targeted) to its pipeline - strengthens the big-pharma race for non-opioid pain assets. This deal directly affects competition with companies like Vertex and will influence licensing/partnering activity in Europe.

✅ Large consumer-health M&A affecting OTC pain supply/brands - 2025 saw high-profile deals in the broader pain/consumer health space (example: the announced Kimberly-Clark bid for Kenvue/Tylenol in Nov 2025) - such consumer-health consolidation can affect Tylenol/OTC channel strategy and pricing in Europe. (Note: corporate/consumer deals like Kenvue materially affect OTC pain market dynamics).

EMA / European Regulatory Activity in 2025:

✅ The EMA (CHMP/PRAC) continued regular reviews in 2025 and published monthly lists of medicines "under evaluation" and meeting highlights; several CHMP meetings in 2025 recommended new medicines, but as of mid/late-2025 there were no widely reported EMA marketing authorisations for an entirely new class pain drug equivalent to JOURNAVX. Companies that win FDA approval often pursue EMA filings afterwards, so watch for EU MAAs for suzetrigine or Tonmya.

✅ EMA publishes monthly 'medicines under evaluation' lists (useful to track whether a pain drug MAA has started).

Major Key Players:

Bayer AG
Haleon
Grünenthal GmbH
ZAMBON COMPANY S.P.A.
Viatris Inc
Pfizer Plc
Kenvue Brands LLC
Adalvo
Mundipharma Ges.m.b.H.
Evotec SE.

Segments Covered in the Europe Pain Management Drugs Market:

By Drug Type: Non-Steroidal Anti-Inflammatory Drugs, Opioids, Corticosteroids, Muscle Relaxants, Anticonvulsant Drugs, Others.

By Indication: Arthritis Pain, Back Pain, Surgery Pain, Headaches & Migraine, Injury Pain, Cancer Pain, Fibromyalgia, Muscle Spasms, Menstrual Pain, Neuropathic Pain, Others.

By Mode of Prescription: Prescription Based, Over-the-Counter.

By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Clinics, Online Pharmacies, Others.

Buy Now & Get 30% OFF - Grab 50% OFF on 2+ reports: https://www.datamintelligence.com/buy-now-page?report=europe-pain-management-drugs-market

Chapter Outline:

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Europe Pain Management Drugs market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Europe Pain Management Drugs Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The Europe Pain Management Drugs market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Europe Pain Management Drugs Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlimited Insights. One Subscription: https://www.datamintelligence.com/reports-subscription

Frequently asked questions:

➠ What is the global sales value, production value, consumption value, import and export of Europe Pain Management Drugs market?

➠ Who are the global key manufacturers of the Europe Pain Management Drugs Industry? How is their operating situation (capacity, production, sales, price, cost, gross, and revenue)?

➠ What are the Europe Pain Management Drugs market opportunities and threats faced by the vendors in the global Europe Pain Management Drugs Industry?

➠ Which application/end-user or product type may seek incremental growth prospects? What is the market share of each type and application?

➠ What focused approach and constraints are holding the Europe Pain Management Drugs market?

➠ What are the different sales, marketing, and distribution channels in the global industry?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.